Inhalational Anthrax Clinical Trial
Official title:
An Open-Label, Randomized, Parallel Group Study to Assess the Safety, Tolerability and Pharmacokinetics of ETI-204 Alone and in the Presence of Ciprofloxacin in Adult Volunteers
Evaluate the safety, tolerability and pharmacokinetics (PK) of intravenous (IV) ETI-204 alone and in the presence of IV and oral ciprofloxacin
An open-label, randomized, parallel group study of IV ETI-204 administered alone and in the
presence of IV and oral ciprofloxacin in 40 adult volunteers.
Subjects will be randomized to two groups of 20 subjects each in a 1:1 ratio. Group 1 will
receive a single IV dose of ETI-204 16 mg/kg followed immediately at the end of the infusion
by a single dose of IV ciprofloxacin (400 mg), followed by oral ciprofloxacin (750 mg) every
12 hours on Days 2-8 with the final oral dose on the morning of Day 9. Group 2 will receive
IV ETI-204 (16 mg/kg) only.
The total duration of the study for each subject will be approximately 100 days divided as
follows:Screening: Days -28 to -2; In-Unit Phases: Days -1, 1 and 2 [all subjects]; Days 8, 9
and 10 [Group 1 only]; Out-of-Unit Visits: Day 9 [Group 2 only]; Day 16 (+/- 3 days); Day 29
(+/- 3 days); Day 43 (+/- 3 days); Final Visit: Day 71 (+/- 3 days).
Following completion of a Screening visit subjects will arrive at the clinical research unit
(CRU) on Day -1 following at least a 10-hour fast. On Day 1, subjects who qualify for entry
into the study will be randomized to receive either ETI-204 plus IV and oral ciprofloxacin
(Group 1) or ETI-204 only (Group 2) in a 1:1 ratio according to the randomization treatment
assignment.
On Day 1, all subjects will receive 50 mg oral diphenhydramine approximately 30 minutes prior
to ETI-204 infusion. Subjects in Group 1 will receive IV ETI-204 16 mg/kg infused over 90
minutes, immediately followed by IV ciprofloxacin 400 mg infused over 60 minutes. Subjects in
Group 2 will receive IV ETI-204 16 mg/kg infused over 90 minutes.
All subjects will be discharged from the CRU on Day 2.
On Days 2 through 8, subjects in Group 1 will receive oral ciprofloxacin (750 mg every 12
hours); the final dose will be received on the morning of Day 9. Oral ciprofloxacin dosing
begins 24 hours after the initiation of the ciprofloxacin infusion on Day 1. Subjects in
Group 1 will return to the CRU on Day 8 and will be discharged from the unit following
completion of PK sampling on Day 10.
Subjects in Group 2 will return to the unit for an out-patient visit on Day 9 but will not be
re-admitted to the CRU for an overnight stay.
All subjects will return to the CRU for out-patient visits on Days 16, 29, 43, and 71.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01929226 -
Safety, Tolerability, and PK of a Single Intravenous Dose of ETI-204 in Adult Volunteers
|
Phase 1 | |
| Completed |
NCT01932437 -
Intramuscular Dose-Escalation Study With ETI-204 in Adult Volunteers
|
Phase 1 | |
| Completed |
NCT01932242 -
Safety, Tolerability and PK of Repeat Administration of Intravenous ETI-204 in Adult Volunteers
|
Phase 1 | |
| Not yet recruiting |
NCT03569553 -
A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax Patients
|